BCL2L1 and malignant colon neoplasm: Notably, MMP-1 (~250-fold, P < 0.01) and IL-6 responsive BCLXL mRNAs were greatly increased after treatment with IL-6 (18 h) in SW480 colon cancer cells under conditions of high (10%) serum (Fig. 1C).